Bristol-Myers Squibb Company (BMY) Q1 2026 (USD): EPS 1.58 (exp. 1.42), revenue 11.5bln (exp. 10.9bln). Reaffirms 2026 guidance with total revenue & adj. EPS trending toward upper end of ranges
- Eliquis revenue 4.14bln, up 16%.
- FY worldwide Eliquis Revenue growth of 10% - 15%.
Context
Bristol-Myers Squibb's Q1 2026 results surpassed expectations on both EPS and revenue, indicating strong performance and growth in the key drug Eliquis. The reaffirmation of 2026 guidance, trending towards the upper end of revenue and EPS ranges, suggests confidence in continuing momentum, which could positively influence investor sentiment and stock performance in the pharmaceuticals sector.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#BRISTOL-MYERS SQUIBB CO#BMY.US#IMPORTANT#FOREX#EQUITIES#METALS#EU SESSION#PHARMACEUTICALS#METALS & MINING#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#BMY#DXY#US EQUITIES